Protagonist Therapeutics Stock Price, News & Analysis (NASDAQ:PTGX)

$18.16 0.59 (3.36 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$17.57
Today's Range$17.65 - $18.72
52-Week Range$8.00 - $23.65
Volume196,148 shs
Average Volume84,259 shs
Market Capitalization$373.96 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.66

About Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics logoProtagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTGX
CUSIPN/A
Phone510-474-0170

Debt

Debt-to-Equity RatioN/A
Current Ratio1.87%
Quick Ratio1.87%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.24 per share
Price / Book3.47

Profitability

Trailing EPS($2.69)
Net Income$-37,170,000.00
Net MarginsN/A
Return on Equity-64.21%
Return on Assets-50.51%

Miscellaneous

Employees35
Outstanding Shares20,480,000

Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics Inc (NASDAQ:PTGX) announced its earnings results on Monday, November, 6th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.40. The business earned $8.78 million during the quarter. View Protagonist Therapeutics' Earnings History.

When will Protagonist Therapeutics make its next earnings announcement?

Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Protagonist Therapeutics.

Where is Protagonist Therapeutics' stock going? Where will Protagonist Therapeutics' stock price be in 2017?

2 Wall Street analysts have issued twelve-month target prices for Protagonist Therapeutics' shares. Their predictions range from $36.00 to $43.00. On average, they anticipate Protagonist Therapeutics' stock price to reach $39.50 in the next year. View Analyst Ratings for Protagonist Therapeutics.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a decline in short interest in October. As of October 31st, there was short interest totalling 405,159 shares, a decline of 41.7% from the October 13th total of 694,616 shares. Based on an average daily trading volume, of 101,910 shares, the days-to-cover ratio is presently 4.0 days. Approximately 3.8% of the company's shares are sold short.

Who are some of Protagonist Therapeutics' key competitors?

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the folowing people:

  • Harold E. Selick Ph.D., Independent Chairman of the Board (Age 62)
  • Dinesh V. Patel Ph.D., President, Chief Executive Officer, Director (Age 59)
  • Thomas P. O'Neil, Chief Financial Officer (Age 51)
  • William A. Hodder, Senior Vice President - Corporate Development (Age 52)
  • David Y. Liu Ph.D., Chief Scientific Officer, Head of Research & Development (Age 66)
  • Ashok Bhandari Ph.D., Vice President - Chemistry (Age 52)
  • Larry Mattheakis Ph.D., Vice President - Biology (Age 59)
  • Mark Smythe Ph.D., Vice President -Technology & Alliances (Age 51)
  • Thamil Annamalai, Senior Director - Pre-clinical Development (Age 56)
  • Richard S. Shames M.D., Chief Medical Officer (Age 56)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who owns Protagonist Therapeutics stock?

Protagonist Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include First Manhattan Co. (0.10%) and Wells Fargo & Company MN (0.05%). Company insiders that own Protagonist Therapeutics stock include Armen Shanafelt, David Y Liu and Richard S Shames. View Institutional Ownership Trends for Protagonist Therapeutics.

Who bought Protagonist Therapeutics stock? Who is buying Protagonist Therapeutics stock?

Protagonist Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co. and Wells Fargo & Company MN. View Insider Buying and Selling for Protagonist Therapeutics.

How do I buy Protagonist Therapeutics stock?

Shares of Protagonist Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of Protagonist Therapeutics stock can currently be purchased for approximately $18.16.

How big of a company is Protagonist Therapeutics?

Protagonist Therapeutics has a market capitalization of $373.96 million. The company earns $-37,170,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Protagonist Therapeutics employs 35 workers across the globe.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560-1160. The company can be reached via phone at 510-474-0170 or via email at [email protected]


MarketBeat Community Rating for Protagonist Therapeutics (PTGX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  158
MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Protagonist Therapeutics (NASDAQ:PTGX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.50$28.50$29.00$26.67
Price Target Upside: 93.75% upside93.75% upside124.46% upside125.61% upside

Protagonist Therapeutics (NASDAQ:PTGX) Consensus Price Target History

Price Target History for Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ:PTGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017BMO Capital MarketsBoost Price TargetOutperform$40.00 -> $43.00N/AView Rating Details
7/21/2017BTIG ResearchInitiated CoverageBuy -> Buy$36.00MediumView Rating Details
9/6/2016Leerink SwannInitiated CoverageOutperform$17.00N/AView Rating Details
9/6/2016BarclaysInitiated CoverageOverweight$18.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Protagonist Therapeutics (NASDAQ:PTGX) Earnings History and Estimates Chart

Earnings by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ PTGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018N/AView Earnings Details
11/6/2017Q3 2017($0.69)($0.29)$8.78 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.19)($0.89)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.61)($0.84)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.49)($0.67)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.58)($0.87)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Protagonist Therapeutics (NASDAQ:PTGX) Earnings Estimates

2017 EPS Consensus Estimate: ($3.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.64)($0.64)($0.64)
Q2 20171($0.92)($0.92)($0.92)
Q3 20171($0.95)($0.95)($0.95)
Q4 20171($0.99)($0.99)($0.99)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Protagonist Therapeutics (NASDAQ:PTGX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Protagonist Therapeutics (NASDAQ PTGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.50%
Institutional Ownership Percentage: 39.68%
Insider Trades by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)
Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ PTGX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2017David Y LiuInsiderSell875$20.00$17,500.00View SEC Filing  
11/13/2017David Y. LiuInsiderSell7,000$16.97$118,790.00View SEC Filing  
10/5/2017Richard S ShamesInsiderSell2,017$19.00$38,323.00View SEC Filing  
9/12/2017Richard S. ShamesInsiderSell3,687$14.31$52,760.97View SEC Filing  
8/29/2017Richard S. ShamesInsiderSell1,512$17.00$25,704.00View SEC Filing  
8/28/2017David Y LiuInsiderSell3,500$15.00$52,500.00View SEC Filing  
7/10/2017David Y. LiuInsiderSell3,500$12.68$44,380.00View SEC Filing  
8/16/2016Armen ShanafeltDirectorBuy583,333$12.00$6,999,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Protagonist Therapeutics (NASDAQ PTGX) News Headlines

Source:
DateHeadline
David Y. Liu Sells 875 Shares of Protagonist Therapeutics Inc (PTGX) StockDavid Y. Liu Sells 875 Shares of Protagonist Therapeutics Inc (PTGX) Stock
www.americanbankingnews.com - December 1 at 11:28 PM
Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 20, 2017Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 20, 2017
finance.yahoo.com - November 21 at 9:35 AM
Protagonist Therapeutics, Inc. (PTGX) Insider David Y. Liu Sells 7,000 SharesProtagonist Therapeutics, Inc. (PTGX) Insider David Y. Liu Sells 7,000 Shares
www.americanbankingnews.com - November 15 at 9:08 PM
Protagonist Therapeutics, Inc. (PTGX) Short Interest Down 41.7% in OctoberProtagonist Therapeutics, Inc. (PTGX) Short Interest Down 41.7% in October
www.americanbankingnews.com - November 14 at 2:56 AM
Comparing Protagonist Therapeutics (PTGX) & Its CompetitorsComparing Protagonist Therapeutics (PTGX) & Its Competitors
www.americanbankingnews.com - November 12 at 3:36 PM
Protagonist Therapeutics, Inc. – Value Analysis (NASDAQ:PTGX) : November 10, 2017Protagonist Therapeutics, Inc. – Value Analysis (NASDAQ:PTGX) : November 10, 2017
finance.yahoo.com - November 12 at 11:57 AM
Zacks Investment Research Upgrades Protagonist Therapeutics, Inc. (PTGX) to "Buy"Zacks Investment Research Upgrades Protagonist Therapeutics, Inc. (PTGX) to "Buy"
www.americanbankingnews.com - November 11 at 6:30 AM
Protagonist Therapeutics, Inc. (PTGX) Forecasted to Post FY2018 Earnings of ($1.82) Per ShareProtagonist Therapeutics, Inc. (PTGX) Forecasted to Post FY2018 Earnings of ($1.82) Per Share
www.americanbankingnews.com - November 10 at 5:38 PM
Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 9, 2017Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 9, 2017
finance.yahoo.com - November 9 at 11:58 AM
Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200
finance.yahoo.com - November 9 at 11:58 AM
Protagonist Therapeutics, Inc. (PTGX) PT Raised to $43.00 at BMO Capital MarketsProtagonist Therapeutics, Inc. (PTGX) PT Raised to $43.00 at BMO Capital Markets
www.americanbankingnews.com - November 7 at 5:44 PM
Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateProtagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 9:11 AM
Protagonist Therapeutics posts 3Q lossProtagonist Therapeutics posts 3Q loss
finance.yahoo.com - November 7 at 9:11 AM
Protagonist Therapeutics, Inc. (PTGX) Issues Quarterly  Earnings Results, Beats Estimates By $0.40 EPSProtagonist Therapeutics, Inc. (PTGX) Issues Quarterly Earnings Results, Beats Estimates By $0.40 EPS
www.americanbankingnews.com - November 7 at 9:06 AM
Protagonist Therapeutics, Inc. (PTGX) Scheduled to Post Quarterly Earnings on MondayProtagonist Therapeutics, Inc. (PTGX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 6:02 AM
Protagonist Therapeutics to Present at the Stifel 2017 Healthcare ConferenceProtagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 2 at 7:58 AM
Protagonist Therapeutics (PTGX) vs. The Competition Head to Head ComparisonProtagonist Therapeutics (PTGX) vs. The Competition Head to Head Comparison
www.americanbankingnews.com - October 23 at 6:34 AM
Protagonist Therapeutics, Inc. (PTGX) Price Target Cut to $40.00Protagonist Therapeutics, Inc. (PTGX) Price Target Cut to $40.00
www.americanbankingnews.com - October 19 at 3:08 PM
Financial Survey: Protagonist Therapeutics (PTGX) versus Its RivalsFinancial Survey: Protagonist Therapeutics (PTGX) versus Its Rivals
www.americanbankingnews.com - October 19 at 9:06 AM
Protagonist Therapeutics, Inc. (PTGX) Lowered to "Hold" at Zacks Investment ResearchProtagonist Therapeutics, Inc. (PTGX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 18 at 6:08 AM
Protagonist Therapeutics, Inc. (PTGX) Insider Sells $38,323.00 in StockProtagonist Therapeutics, Inc. (PTGX) Insider Sells $38,323.00 in Stock
www.americanbankingnews.com - October 10 at 10:29 PM
 Analysts Expect Protagonist Therapeutics, Inc. (PTGX) to Announce -$0.95 EPS Analysts Expect Protagonist Therapeutics, Inc. (PTGX) to Announce -$0.95 EPS
www.americanbankingnews.com - September 25 at 12:24 AM
Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
finance.yahoo.com - September 22 at 2:39 PM
Analysts Issue Forecasts for Protagonist Therapeutics, Inc.s FY2019 Earnings (PTGX)Analysts Issue Forecasts for Protagonist Therapeutics, Inc.'s FY2019 Earnings (PTGX)
www.americanbankingnews.com - September 22 at 12:52 PM
/C O R R E C T I O N -- Protagonist Therapeutics, Inc.//C O R R E C T I O N -- Protagonist Therapeutics, Inc./
finance.yahoo.com - September 15 at 7:51 AM
Protagonist Therapeutics, Inc. (PTGX) Insider Richard S. Shames Sells 3,687 SharesProtagonist Therapeutics, Inc. (PTGX) Insider Richard S. Shames Sells 3,687 Shares
www.americanbankingnews.com - September 12 at 10:16 PM
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceProtagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 12 at 8:50 AM
Protagonist Therapeutics (PTGX) and Jaguar Animal Health (JAGX) Critical ComparisonProtagonist Therapeutics (PTGX) and Jaguar Animal Health (JAGX) Critical Comparison
www.americanbankingnews.com - September 1 at 6:06 AM
Insider Selling: Protagonist Therapeutics, Inc. (PTGX) Insider Sells 1,512 Shares of StockInsider Selling: Protagonist Therapeutics, Inc. (PTGX) Insider Sells 1,512 Shares of Stock
www.americanbankingnews.com - August 30 at 8:50 PM
Protagonist Therapeutics, Inc. (PTGX) Insider David Y. Liu Sells 3,500 SharesProtagonist Therapeutics, Inc. (PTGX) Insider David Y. Liu Sells 3,500 Shares
www.americanbankingnews.com - August 29 at 10:34 PM
Protagonist Therapeutics, Inc. (PTGX) Receives Average Rating of "Buy" from BrokeragesProtagonist Therapeutics, Inc. (PTGX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 29 at 12:40 AM
Protagonist Therapeutics (PTGX) Announces Closing of Janssen Pact for PTG-200 and Receipt of $50M PaymentProtagonist Therapeutics (PTGX) Announces Closing of Janssen Pact for PTG-200 and Receipt of $50M Payment
www.streetinsider.com - August 25 at 10:23 AM
Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million PaymentProtagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment
finance.yahoo.com - August 25 at 10:23 AM
Protagonist Therapeutics, Inc. (PTGX) Expected to Post Earnings of -$0.95 Per ShareProtagonist Therapeutics, Inc. (PTGX) Expected to Post Earnings of -$0.95 Per Share
www.americanbankingnews.com - August 18 at 6:12 PM
Leerink Swann Research Analysts Raise Earnings Estimates for Protagonist Therapeutics, Inc. (PTGX)Leerink Swann Research Analysts Raise Earnings Estimates for Protagonist Therapeutics, Inc. (PTGX)
www.americanbankingnews.com - August 17 at 8:04 AM
Protagonist Therapeutics, Inc. (PTGX) Issues Quarterly  Earnings Results, Misses Estimates By $0.70 EPSProtagonist Therapeutics, Inc. (PTGX) Issues Quarterly Earnings Results, Misses Estimates By $0.70 EPS
www.americanbankingnews.com - August 9 at 4:46 PM
Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business HighlightsProtagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights
finance.yahoo.com - August 9 at 6:40 AM
Brokerages Expect Protagonist Therapeutics, Inc. (PTGX) to Announce ($0.92) Earnings Per ShareBrokerages Expect Protagonist Therapeutics, Inc. (PTGX) to Announce ($0.92) Earnings Per Share
www.americanbankingnews.com - July 30 at 10:04 PM
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Coverage Initiated by Analysts at BTIG ResearchProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - July 22 at 7:03 PM
David Y. Liu Sells 3,500 Shares of Protagonist Therapeutics, Inc. (PTGX) StockDavid Y. Liu Sells 3,500 Shares of Protagonist Therapeutics, Inc. (PTGX) Stock
www.americanbankingnews.com - July 12 at 8:42 PM
Brokerages Expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to Announce ($0.92) EPSBrokerages Expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to Announce ($0.92) EPS
www.americanbankingnews.com - July 12 at 4:18 PM
-$0.92 Earnings Per Share Expected for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) This Quarter-$0.92 Earnings Per Share Expected for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) This Quarter
www.americanbankingnews.com - July 7 at 10:53 AM
Protagonist Therapeutics Inc. (PTGX) Jumped On Janssen Biotech DealProtagonist Therapeutics Inc. (PTGX) Jumped On Janssen Biotech Deal
www.rttnews.com - May 31 at 1:01 PM
Can Protagonist Therapeutics Stock Still Double After Its Huge Gain?Can Protagonist Therapeutics Stock Still Double After Its Huge Gain?
247wallst.com - May 30 at 7:03 PM
Protagonist Therapeutics Inc. (PTGX) Is Up Sharply On Collaboration AgreementProtagonist Therapeutics Inc. (PTGX) Is Up Sharply On Collaboration Agreement
www.nasdaq.com - May 30 at 7:03 PM
Protagonist Therapeutics Spikes Sharply After Agreement With JanssenProtagonist Therapeutics Spikes Sharply After Agreement With Janssen
feeds.benzinga.com - May 30 at 11:43 AM
Protagonist Therapeutics (PTGX) Awarded $1.34M in SBIR Funding for Development of Biomarkers of IL-23 Receptor AntagonistProtagonist Therapeutics (PTGX) Awarded $1.34M in SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist
www.streetinsider.com - May 25 at 12:40 AM
PROTAGONIST THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal OfficersPROTAGONIST THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 9 at 10:06 PM
Protagonist Therapeutics (PTGX) Initiates Phase 2b Study of PTG-100 in UlcerativeProtagonist Therapeutics (PTGX) Initiates Phase 2b Study of PTG-100 in Ulcerative
www.streetinsider.com - January 18 at 7:58 PM
Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative ColitisProtagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
us.rd.yahoo.com - January 17 at 10:52 AM

SEC Filings

Protagonist Therapeutics (NASDAQ:PTGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Protagonist Therapeutics (NASDAQ:PTGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Protagonist Therapeutics (NASDAQ PTGX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.